No Data
StemRIM Begins Phase 2 Trial for Cardiomyopathy Treatment
Stocks that moved the previous day part2: Timee, Heartseed, N.C.N, ETC.
Stock Name <Code> Closing Price on the 13th ⇒ Change from the previous day Kurazushi <2695> 3140 -115 Continuing to view negatively the abolition of the shareholder benefit system, IHI <7013> 8278 -452 Cautious views regarding defense tax increase have been conveyed. Omron <6645> 4892 -292 There seems to be a sense of completion regarding expectations for China’s policy moves. Kawasaki Heavy Industries <7012> 6410 -214 Major defense-related stocks are generally under selling pressure. Mitsubishi Heavy Industries <7011> 2291.5 -98.5 Core defense-related.
StemRIM Secures AMED Grant for Gene Therapy Development
Stocks that moved the previous day part 2: Metaplanet, Pluszero, eWeLL ETC.
Stock name <code> Closing price on the 12th ⇒ Change from the previous day Synchro Food <3963> 382 -35 Announced public offering and sale, leading to concerns about dilution and supply-demand in the short term. Pharma Foods <2929> 915 -43 Significant increase in profits in the first quarter, but the surprises are few. Tsuburaya Productions HD <2767> 1881 -32 High level of margin purchases is still noted during the decline. Fixstars <3687> 1850 -84 Related to quantum computers, saw a significant increase on the 11th.
Emerging Markets stock digest: Kaiom rebounds significantly, pluszero surges.
<4599> Stem Inc reduced by 19 to 324. The company's performance for the first quarter of the fiscal year ending July 2025 was announced; there was no business revenue (no business revenue in the same period last year), an operating loss of 0.573 billion yen (compared to an operating loss of 0.491 billion yen), a recurring loss of 0.573 billion yen (compared to a recurring loss of 0.491 billion yen), and a quarterly net loss of 0.56 billion yen (compared to a quarterly net loss of 0.467 billion yen), indicating an expanded deficit. The company's business revenue is primarily composed of milestone income due to development progress, and the proposal.
Stem Inc --- Continuing to decline, discontent with the performance for the first quarter of the fiscal year ending July 2025.
Decline continues. The performance for the first quarter of the fiscal year ending July 2025 has been announced, with no revenue from operations (no revenue from operations in the same period of the previous year), an operating loss of 0.573 billion yen (an operating loss of 0.491 billion yen in the same period), an ordinary loss of 0.573 billion yen (an ordinary loss of 0.491 billion yen in the same period), and a quarterly net loss of 0.56 billion yen (a quarterly net loss of 0.467 billion yen in the same period), indicating an expanded deficit. The company's operational revenue is primarily driven by milestone income associated with development progress, which is significantly affected by the development strategies and schedules of its partners.
No Data